MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
5:30 AM | Thursday | Oct 22, 2026 Fool - Investing News

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

NEW News Thumbnail
6:51 PM | Wednesday | Oct 21, 2026 Zacks Investment Research

Moderna (MRNA) Rises Higher Than Market: Key Facts

News Thumbnail
11:00 AM | Wednesday | Oct 21, 2026 Market Watch

Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.

News Thumbnail
10:25 AM | Wednesday | Oct 21, 2026 Zacks Investment Research

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

News Thumbnail
4:02 AM | Wednesday | Oct 21, 2026 The Motley Fool

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

News Thumbnail
11:00 AM | Wednesday | Oct 21, 2026 Market Watch

Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.

News Thumbnail
10:25 AM | Wednesday | Oct 21, 2026 Zacks Investment Research

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

News Thumbnail
4:02 AM | Wednesday | Oct 21, 2026 The Motley Fool

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

News Thumbnail
1:53 PM | Tuesday | Oct 20, 2026 24/7 Wall Street

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

News Thumbnail
10:37 AM | Monday | Oct 19, 2026 Benzinga

What's Going On With Moderna Stock Monday?

News Thumbnail
10:31 AM | Monday | Oct 19, 2026 MarketBeat

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

News Thumbnail
8:45 AM | Sunday | Oct 18, 2026 The Motley Fool

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

News Thumbnail
12:23 PM | Saturday | Oct 17, 2026 The Motley Fool

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

News Thumbnail
8:45 AM | Saturday | Oct 17, 2026 Fool - Investing News

The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going

News Thumbnail
12:44 PM | Friday | Oct 16, 2026 24/7 Wall Street

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

News Thumbnail

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

Fool - Investing News

5:30 AM | Thursday | Oct 22, 2026

news photo
Loading...

Both of these ETFs look the part, but only one is truly the better buy for investors.

Read full article redirect
5:30 AM | Thursday | Oct 22, 2026

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

Fool - Investing News

Both of these ETFs look the part, but only one is truly the better buy for investors.

Read full article arrow
NEW News Thumbnail
6:51 PM | Wednesday | Oct 21, 2026

Moderna (MRNA) Rises Higher Than Market: Key Facts

Zacks Investment Research

The latest trading day saw Moderna (MRNA) settling at $245.81, representing a +1.54% change from its previous close.

Read full article arrow
News Thumbnail
11:00 AM | Wednesday | Oct 21, 2026

Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.

Market Watch

Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.

Read full article arrow
News Thumbnail
10:25 AM | Wednesday | Oct 21, 2026

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

Zacks Investment Research

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.

Read full article arrow
News Thumbnail
4:02 AM | Wednesday | Oct 21, 2026

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

The Motley Fool

Moderna's coronavirus vaccine generated blockbuster revenue, but demand declined in the later stages of the pandemic. The company's oncology pipeline is advancing, and a potential product may be on the horizon.

Read full article arrow
News Thumbnail
11:00 AM | Wednesday | Oct 21, 2026

Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.

Market Watch

Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.

Read full article arrow
News Thumbnail
10:25 AM | Wednesday | Oct 21, 2026

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

Zacks Investment Research

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.

Read full article arrow
News Thumbnail
4:02 AM | Wednesday | Oct 21, 2026

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

The Motley Fool

Moderna's coronavirus vaccine generated blockbuster revenue, but demand declined in the later stages of the pandemic. The company's oncology pipeline is advancing, and a potential product may be on the horizon.

Read full article arrow
News Thumbnail
1:53 PM | Tuesday | Oct 20, 2026

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

24/7 Wall Street

Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.

Read full article arrow
News Thumbnail
10:37 AM | Monday | Oct 19, 2026

What's Going On With Moderna Stock Monday?

Benzinga

Moderna Inc. (NASDAQ:MRNA) shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its personalized cancer therapy this Saturday and after BofA raised its price target.

Read full article arrow
News Thumbnail
10:31 AM | Monday | Oct 19, 2026

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

MarketBeat

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

Read full article arrow
News Thumbnail
8:45 AM | Sunday | Oct 18, 2026

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

The Motley Fool

The recent meteoric rally of MRNA shares has made Moderna a massive company. Its market cap has grown so large, in fact, that it's earned a place among Nasdaq's largest listings.

Read full article arrow
News Thumbnail
12:23 PM | Saturday | Oct 17, 2026

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

The Motley Fool

A 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program. With 14 pivotal trials underway, including seven for pumitamig, BioNTech's oncology pipeline is moving well beyond early-stage research.

Read full article arrow
News Thumbnail
8:45 AM | Saturday | Oct 17, 2026

The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going

Fool - Investing News

Momentum is only half the battle. Their underlying companies still need to justify the continued bullishness of their stocks.

Read full article arrow
News Thumbnail
12:44 PM | Friday | Oct 16, 2026

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

24/7 Wall Street

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.

Read full article arrow
News Thumbnail